Biopharmaceutical Company Receives U.S. Patent Notice For Neurodegenerative Disease Treatment

Synaptogenix Receives Notice of Allowance for U.S. Patent Application: A Step Forward in the Treatment of Neurodegenerative Diseases.

This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Synaptogenix, Inc. (NASDAQ: SNPX) has recently made headlines with its significant achievement in the field of neurodegenerative disease treatment. The pioneering biopharmaceutical company has received a Notice of Allowan…